Cardiome Highlights Partner SteadyMed´s Agreement with the FDA on Pathway to TREVYENT NDA Resubmission
(WorldNews Canada)

NASDAQ:CRMETSX:COM CARDIOME HIGHLIGHTS PARTNER STEADYMED`S AGREEMENT WITH FDA ON PATHWAY TO TREVYENT NDA RESUBMISSION NDA Expected to be Filed and Accepted by the End of 2018 Vancouver, Canada, December 11, 2017 - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today highlighted that its partner SteadyMed Therapeutics (NASDAQ:STDY) has reached agreement with the U.S. Food and Drug Administration (FDA) on the work necessary to resubmit the New Drug Application (NDA) for Trevyent® for the treatment of pulmonary arterial hypertension (PAH). Based on written feedback received from the FDA, SteadyMed...